title: NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
authors.forename: Fiona
authors.initials: F
authors.lastname: Rinaldi
authors.forename: Elisabeth
authors.initials: E
authors.lastname: George
authors.forename: Amanda I
authors.initials: AI
authors.lastname: Adler
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000556:secondary*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D000077544:Panitumumab; D017410:Practice Guidelines as Topic; D013222:State Medicine / Q000191:economics; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000077544:Panitumumab; D000068818:Cetuximab